San Francisco startup Simile has closed a $200M Series B at a $2 billion post-money valuation, doubling the company's price tag just five months after emerging from stealth with a $100M Series A led by Index Ventures. Greenoaks led the new round on July 30, 2026, with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures.
From Stanford's Smallville To Enterprise Digital Twins
Simile is building foundation models of human behavior, effectively turning years of Stanford research into a commercial platform for enterprise product and policy testing. Its founder and CEO, Joon Sung Park, first attracted attention with the Smallville project — an academic demonstration in which AI agents carried on plausible simulated lives inside a virtual town, complete with parties, gossip and daily routines.
Simile productizes that same idea for enterprises. Its simulations aim to predict how real people will respond to a new drug regimen, a marketing message or a product change, letting brands and agencies run what the company calls "synthetic RCTs" before spending on real-world trials.
Marquee Customers And A Cash-Rich AI Unicorn Club
CVS Health, Wealthfront and polling firm Gallup are named customers. CVS is also now an investor — a common pattern in the current agentic-AI cycle, where large customers convert their commercial exposure into equity stakes to lock in preferred access to models and roadmaps.
According to Simile, revenue has grown fivefold since it emerged from stealth in February. That trajectory — plus Greenoaks' preference for concentrated growth-stage bets — helps explain how a company barely a year past its Series A can command a $2 billion valuation. The AI unicorn club is filling in fast; Simile now shares the ranks with peers like Rhoda AI and Genesis AI.
Where The Money Goes
Simile said proceeds will accelerate technical training of its human-behavior foundation models, expand its simulation compute layers and scale commercial engineering across enterprise healthcare, financial services and media. The company plans to build out research on high-fidelity digital twins that can, in Park's stated ambition, one day simulate "all eight billion people on earth, accurately and honestly." Whether that goal is closer to science or marketing, the checks are real.
The Series B also positions Simile against a growing crop of synthetic-research startups. Aaru raised a $1B-headline Series A in December 2025; other players in the space include CDS Health-backed research platforms and enterprise-grade market-simulation vendors. See our related coverage on enterprise AI control planes and AI agent governance for how the broader agentic stack is capitalising.
Reporting based on coverage from TechCrunch, Yahoo Finance and FinSMEs.